Consolidated Statement Of Cash Flows (USD $)	9 Months Ended		65 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (2,150,617)	$ (1,559,294)	$ (11,699,364)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	145,115	157,490	936,578
Technology impairment	345,000		690,000
Common stock issued for services	18,500		318,500
Stock options and warrants	45,481	363,562	2,995,850
(Increase) decrease in assets
Grants receivable		244,479
Prepaid drug product for testing	73,500	88,400	(79,500)
Other current assets	3,044	20,967	(45,395)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(47,559)	(41,761)	268,572
Net cash used in operating activities	(1,567,536)	(726,157)	(6,614,759)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	(25,000)	(62,547)	(884,710)
Net cash used in investing activities	(25,000)	(62,547)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes			435,000
Cash repayment of convertible notes			(15,000)
Net proceeds from sale of common stock	973,146	1,533,425	7,412,331
Net cash from financing activities	973,146	1,533,425	7,832,331
NET INCREASE (DECREASE) IN CASH	(619,390)	744,721	332,862
Cash, beginning of period	952,252	238,565
Cash, end of period	332,862	983,286	332,862
Cash paid for
Interest			445
Income taxes
Non-cash financing activities
Common stock issued upon conversion of convertible notes			420,000
Placement Agent
Non-cash financing activities
Common stock issued		179,421	591,566
MD Anderson for License
Non-cash financing activities
Common stock issued			2,354,167
LPC
Non-cash financing activities
Common stock issued			$ 210,755